Can the Present Canadian Health Care System Provide Evidence-Based Pharmaceutical Care? Consideration of Two Important Cardiovascular Clinical Contexts
Current Canadian drug review decisions are complex and coverage decisions vary widely, resulting in an inability to provide guideline-recommended CV evidence-based medicine. In developing future pharmacare programs, it is crucial to centralise the drug review process and integrate mechanisms to incorporate up-to-date evidence.
Authors
- Quinton Barry (ORCID: https://orcid.org/0000-0001-8675-9509)
- Jean‐François Tanguay (ORCID: https://orcid.org/0000-0003-1057-0528)
- Aun‐Yeong Chong (ORCID: https://orcid.org/0000-0001-8172-5318)
- Marie Lordkipanidzé (ORCID: https://orcid.org/0000-0001-7418-6766)
- Morgane Laverdure (ORCID: https://orcid.org/0000-0002-7993-0838)
- Cole Clifford
- Rene Boudreau (ORCID: https://orcid.org/0000-0002-3844-506X)
- Derek So (ORCID: https://orcid.org/0000-0002-3909-5698)
- William Knoll
Institutions
- University of Ottawa (CA)
- University of Toronto (CA)
- Montreal Heart Institute (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Canadian Journal of Cardiology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1016/j.cjca.2024.09.014
- Citations
- 2
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.69